IT security incident to hurt revenue of few businesses of Sun Pharma

Sun Pharma said it took steps to remediate the impact with the help of experts and enhanced security measures to address the situation.

Published On 2023-03-27 09:15 GMT   |   Update On 2023-03-27 12:50 GMT

Bengaluru: Indian drugmaker Sun Pharmaceutical Industries Ltd would see a revenue drop in a few of its businesses and incur some expenses due to an "IT security incident" that happened earlier this month.The effect of the incident on the drug major's IT systems included a breach of certain file systems and theft of some company and personal data, Sun Pharma said in a filing late on Sunday....

Login or Register to read the full article

Bengaluru: Indian drugmaker Sun Pharmaceutical Industries Ltd would see a revenue drop in a few of its businesses and incur some expenses due to an "IT security incident" that happened earlier this month.

The effect of the incident on the drug major's IT systems included a breach of certain file systems and theft of some company and personal data, Sun Pharma said in a filing late on Sunday. A ransomware group has claimed responsibility for the incident, it added.

Sun Pharma, known for its consumer healthcare products such as Revital vitamins and pain relief medicine Volini, posted a near 14% jump in total revenue from operations to 112.41 billion rupees ($1.37 billion) in the last quarter.

The drugmaker on March 2 reported the information security incident, adding that it had not impacted the company's operations. However, on Sunday, the company said its containment measures had affected its operations.

Sun Pharma said it took steps to remediate the impact with the help of experts and "enhanced" security measures to address the situation.

The company said it was unable to determine other potential adverse impacts of the incident, including higher costs and the possibility of litigation

Read also: Information security incident occurred at Sun Pharma, impacted IT assets isolated


Tags:    
Article Source : Reuters

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News